Showing results (81-90 of 790) with videos related to
Sort By:
Pageof 79
Cancer Treatment and Research|October 4, 2016
Management of Transplant-Eligible Patients with Newly Diagnosed Multiple MyelomaJacob Laubach, Shaji KumarExpert Opinion on Drug Safety|September 30, 2022
An update on the safety of ixazomib for the treatment of multiple myelomaUtkarsh Goel, Shaji KumarLeukemia & Lymphoma|July 26, 2021
Disease heterogeneity, prognostication and the role of targeted therapy in multiple myelomaSaurabh Zanwar, Shaji KumarLeukemia & Lymphoma|January 12, 2018
PI3K/AKT/mTOR pathway in multiple myeloma: from basic biology to clinical promiseVijay Ramakrishnan, Shaji KumarAmerican Journal of Hematology|October 17, 2022
Prevention of infections including vaccination strategies in multiple myelomaHeinz Ludwig, Shaji KumarClinical Medicine Insights. Oncology|March 16, 2013
Efficacy of bortezomib as first-line treatment for patients with multiple myelomaUtkarsh Painuly, Shaji KumarOncology and Therapy|February 22, 2021
Post-Transplant Maintenance Treatment Options in Multiple MyelomaDhauna Karam, Shaji KumarLeukemia & Lymphoma|December 22, 2024
Risk-adapted treatment for multiple myeloma: assessing the current potential and a roadmap for the futureSaurabh Zanwar, Shaji KumarClinical Lymphoma, Myeloma & Leukemia|August 21, 2019
SOHO State of the Art Updates and Next Questions: T-Cell-Directed Immune Therapies for Multiple Myeloma: Chimeric Antigen Receptor-Modified T Cells and Bispecific T-Cell-Engaging AgentsDeepu Madduri, Madhav V Dhodapkar, Sagar Lonial, et al.Molecular Cancer Therapeutics|September 15, 2011
The NEDD8-activating enzyme inhibitor, MLN4924, cooperates with TRAIL to augment apoptosis through facilitating c-FLIP degradation in head and neck cancer cellsLiqun Zhao, Ping Yue, Sagar Lonial, et al.Pageof 79